Atezolizumab + obinutuzumab + venetoclax in patients with R/R DLBCL

Atezolizumab + obinutuzumab + venetoclax in patients with R/R DLBCL

LYSA: atezolizumab, obinutuzumab and venetoclax in R/R DLBCLПодробнее

LYSA: atezolizumab, obinutuzumab and venetoclax in R/R DLBCL

Atezolizumab-obinutuzumab-venetoclax in follicular lymphoma and MZLПодробнее

Atezolizumab-obinutuzumab-venetoclax in follicular lymphoma and MZL

Obinutuzumab plus venetoclax in early R/R DLBCLПодробнее

Obinutuzumab plus venetoclax in early R/R DLBCL

The safety of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) in R/R MCLПодробнее

The safety of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) in R/R MCL

Overview of a Phase Ib study of venetoclax and obinutuzumab in CLLПодробнее

Overview of a Phase Ib study of venetoclax and obinutuzumab in CLL

Trial results of venetoclax plus CHOP therapy with rituximab or obinutuzumab in non-Hodgkin lymphomaПодробнее

Trial results of venetoclax plus CHOP therapy with rituximab or obinutuzumab in non-Hodgkin lymphoma

CLL14 trial: do certain patients benefit more from venetoclax plus obinutuzumab in CLL?Подробнее

CLL14 trial: do certain patients benefit more from venetoclax plus obinutuzumab in CLL?

Atezolizumab with venetoclax and obinutuzumab in patients with CLLПодробнее

Atezolizumab with venetoclax and obinutuzumab in patients with CLL

Atezolizumab, Obinutuzumab, and Venetoclax provide durable remissions for untreated DLBCL-RS ptsПодробнее

Atezolizumab, Obinutuzumab, and Venetoclax provide durable remissions for untreated DLBCL-RS pts

Dr. Gerson on Venetoclax/Obinutuzumab Combination in CLLПодробнее

Dr. Gerson on Venetoclax/Obinutuzumab Combination in CLL

Venetoclax and obinutuzumab for CLLПодробнее

Venetoclax and obinutuzumab for CLL

Ideal patient for Venetoclax/Obinutuzumab combination | Dr. Jeff Sharman | Oncology Brothers #2023Подробнее

Ideal patient for Venetoclax/Obinutuzumab combination | Dr. Jeff Sharman | Oncology Brothers #2023

Obinutuzumab + Venetoclax for Frontline CLLПодробнее

Obinutuzumab + Venetoclax for Frontline CLL

Insights into the MAJIC study: acalabrutinib + venetoclax vs venetoclax + obinutuzumab in CLLПодробнее

Insights into the MAJIC study: acalabrutinib + venetoclax vs venetoclax + obinutuzumab in CLL

CLL14: Venetoclax plus obinutuzumab for CLLПодробнее

CLL14: Venetoclax plus obinutuzumab for CLL

5-year follow-up results of CLL14: obinutuzumab + venetoclax vs obinutuzumab + chlorambucil in CLLПодробнее

5-year follow-up results of CLL14: obinutuzumab + venetoclax vs obinutuzumab + chlorambucil in CLL

MAJIC: Venetoclax with acalabrutinib or obinutuzumab in CLLПодробнее

MAJIC: Venetoclax with acalabrutinib or obinutuzumab in CLL

Acalabrutinib, venetoclax and obinutuzumab in previously untreated patients with CLLПодробнее

Acalabrutinib, venetoclax and obinutuzumab in previously untreated patients with CLL

Venetoclax and Obinutuzumab in CLLПодробнее

Venetoclax and Obinutuzumab in CLL